International Journal of
Reproductive Biomedicine
Wed, Apr 24, 2024
[Archive]
Volume 15, Issue 6 (7-2017)
IJRM 2017, 15(6): 351-356 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Taheripanah R, Zamaniyan M, Moridi A, Taheripanah A, Malih N. Comparing the effect of gonadotropin-releasing hormone agonist and human chorionic gonadotropin on final oocytes for ovulation triggering among infertile women undergoing intrauterine insemination: An RCT. IJRM 2017; 15 (6) :351-356
URL: http://ijrm.ir/article-1-833-en.html
URL: http://ijrm.ir/article-1-833-en.html
1- Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Infertility Center, Department of Obstetrics and Gynecology, Mazandaran University of Medical Sciences, Sari, Iran , marziehzamaniyan@gmail.com
3- Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
4- Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Infertility Center, Department of Obstetrics and Gynecology, Mazandaran University of Medical Sciences, Sari, Iran , marziehzamaniyan@gmail.com
3- Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
4- Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (4893 Views)
Background: The purpose of triggering in ovulation induction is to induce the final maturation of oocytes and their release from the ovary for fertilization.
Objective: The aim of the present study was to compare the effectiveness of gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (HCG) on the final maturation of oocytes and pregnancy rates in intrauterine insemination (IUI) cycles.
Materials and Methods: In this randomized clinical trial, 110 infertile women who were selected for IUI entered the study. Ovulation induction was performed. Group I received 0.1 mg GnRH agonist as triggering and group II received 10,000 IU of HCG. The serum Estradiol (E2), Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH) levels were measured at 12 and 36 hr after injection.
Results: LH surge was detected in all patients. LH levels at 12 and 36 hr after triggering was higher in Group I and it washed out earlier than group II (p=0.00). The pregnancy rate was higher in Group I, but the difference was not statistically significant (26.9% vs. 20.8%, respectively p=0.46). Also, the incidence of ovarian hyperstimulation syndrome was not different between the two groups (p=0.11). There was a significant difference regarding the estradiol levels at 36 hours after triggering (p=0.00).
Conclusion: Effects of GnRH on endogenous LH surge is sufficient for oocyte releasing and final follicular maturation. Pregnancy rates and ovarian hyperstimulation syndrome incidence were not different between the groups. We suggest that GnRH agonists might be used as an alternative option instead of HCG in IUI cycles.
Objective: The aim of the present study was to compare the effectiveness of gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (HCG) on the final maturation of oocytes and pregnancy rates in intrauterine insemination (IUI) cycles.
Materials and Methods: In this randomized clinical trial, 110 infertile women who were selected for IUI entered the study. Ovulation induction was performed. Group I received 0.1 mg GnRH agonist as triggering and group II received 10,000 IU of HCG. The serum Estradiol (E2), Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH) levels were measured at 12 and 36 hr after injection.
Results: LH surge was detected in all patients. LH levels at 12 and 36 hr after triggering was higher in Group I and it washed out earlier than group II (p=0.00). The pregnancy rate was higher in Group I, but the difference was not statistically significant (26.9% vs. 20.8%, respectively p=0.46). Also, the incidence of ovarian hyperstimulation syndrome was not different between the two groups (p=0.11). There was a significant difference regarding the estradiol levels at 36 hours after triggering (p=0.00).
Conclusion: Effects of GnRH on endogenous LH surge is sufficient for oocyte releasing and final follicular maturation. Pregnancy rates and ovarian hyperstimulation syndrome incidence were not different between the groups. We suggest that GnRH agonists might be used as an alternative option instead of HCG in IUI cycles.
Keywords: Gonadotropin-Releasing Hormone, Chorionic gonadotropin, Insemination, Artificial, Ovulation, Pregnancy.
Type of Study: Original Article |
References
1. Farag AH, El-deen MHN, Hassan RM. Triggering ovulation with gonadotropin-releasing hormone agonist versus human chorionic gonadotropin in polycystic ovarian syndrome. A randomized trial. Middle East Fertil Soc J 2015; 20: 217-223. [DOI:10.1016/j.mefs.2015.01.002]
2. Orvieto R. Triggering final follicular maturation-hCG, GnRH-agonist or both, when and to whom? J Assist Reprod Genet 2016; 33: 1415-1416. [DOI:10.1007/s10815-016-0775-4]
3. Prapas N, Tavaniotou A, Panagiotidis Y, Prapa S, Kasapi E, Goudakou M, et al. Low-dose human chorionic gonadotropin during the proliferative phase may adversely affect endometrial receptivity in oocyte recipients. Gynecol Endocrinol 2009; 25: 53-59. [DOI:10.1080/09513590802360769]
4. Yen SS. The human menstrual cycle: neuroendocrine regulation. Reprod Endocrinol 1991: 273-308.
5. Kol S, Humaidan P. LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango? Reprod Biomed Online 2010; 21: 590-592. [DOI:10.1016/j.rbmo.2010.06.031]
6. Humaidan P, Kol S, Papanikolaou E. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011; 17: 510-524. [DOI:10.1093/humupd/dmr008]
7. Haas J, Ophir L, Barzilay E, Yerushalmi GM, Yung Y, Kedem A, et al. GnRH agonist vs. hCG for triggering of ovulation-differential effects on gene expression in human granulosa cells. PLoS One 2014; 9: e90359. [DOI:10.1371/journal.pone.0090359]
8. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010; 94: 389-400. [DOI:10.1016/j.fertnstert.2010.03.028]
9. Griesinger G, Diedrich K, Devroey P, Kolibianakis E. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006; 12: 159-168. [DOI:10.1093/humupd/dmi045]
10. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310-315. [DOI:10.1016/S0015-0282(00)01675-7]
11. Gülekli B, Göde F, Sertkaya Z, Işık AZ. Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series. J Turkish German Gynecol Assoc 2015; 16: 35. [DOI:10.5152/jtgga.2015.15084]
12. Talwar P, Sharma R, Sandeep K, Sareen S, Duggal B. Embryo reduction: our experience. Med J Armed Forces India 2011; 67: 241-244. [DOI:10.1016/S0377-1237(11)60050-6]
13. Buckett W, Bentick B, Shaw R. Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose. Hum Reprod 1998; 13: 811-814. [DOI:10.1093/humrep/13.4.811]
14. Lin M-H, Wu FS-Y, Lee RK-K, Li S-H, Lin S-Y, Hwu Y-M. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril 2013; 100: 1296-1302. [DOI:10.1016/j.fertnstert.2013.07.1976]
15. Soliman BS, Siam S. Pregnancy rate after ovulation triggering with gonadotrophin releasing hormone agonist versus human chorionic gonadotrophin in women undergoing controlled ovarian stimulation/intrauterine insemination. Middle East Fertil Soc J 2014; 19: 262-267. [DOI:10.1016/j.mefs.2013.08.002]
16. Humaidan P, Kol S, Papanikolaou E. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011; 17: 510-524. [DOI:10.1093/humupd/dmr008]
17. Gonen Y, Dirnfeld M, Goldman S, Koifman M, Abramovici H. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF). J Assist Reprod Genet 1991; 8: 254-259. [DOI:10.1007/BF01139780]
18. Cerrillo M, Pacheco A, Rodríguez S, Gómez R, Delgado F, Pellicer A, et al. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. Fertil Steril 2011; 95: 2517-2519 [DOI:10.1016/j.fertnstert.2010.12.054]
19. Alyasin A, Mehdinejadiani S, Ghasemi M. GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. Int J Reprod BioMed 2016; 14: 557
20. Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? J Assist Reprod Genet 2008; 25: 63-66. [DOI:10.1007/s10815-008-9198-1]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
